Results 21 to 30 of about 11,568,194 (143)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls [PDF]

Diagnostics, 2023
In June 2021, the US Federal Drug and Food Administration (FDA) granted accelerated approval for the antibody aducanumab and, in January 2023, also for the antibody lecanemab, based on a perceived drug-induced removal of cerebral amyloid-beta as assessed
Poul F. Høilund-Carlsen, Mona-Elisabeth Revheim, Tommaso Costa, Kasper P. Kepp, Rudolph J. Castellani, George Perry, Abass Alavi, Jorge R. Barrio   +7 more
doaj   +2 more sources

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 [PDF]

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +2 more sources

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications [PDF]

Frontiers in Neuroscience
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Sarah J. Doran, Russell P. Sawyer
doaj   +2 more sources

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer’s disease and a literature review [PDF]

BMC Neurology
Objective To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease (AD) patients treated with lecanemab.
Yingte Wang, Qun Yu, Bin Chen, Jing Zhou, Zhiming Li, Wang Liao, Jun Liu, Airong Yang   +7 more
doaj   +2 more sources

Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE. [PDF]

J Prev Alzheimers Dis
Amyloid-β-directed monoclonal antibody therapies may lead to amyloid-related imaging abnormalities (ARIA). Clinical trials that formed the basis for the ARIA radiographic severity grading scale adopted by the approved drugs' labels utilized T2* gradient ...
Sima DM, Phan TV, Franceschi AM, Gibbs WN, Barkhof F, Scheltens P, Salloway S, Cummings J, Van Hecke W, Smeets D.   +9 more
europepmc   +4 more sources

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a studyResearch in context

EBioMedicine, 2023
Summary: Background: Anti-amyloid vaccines may offer a convenient, affordable, and accessible means of preventing and treating Alzheimer's disease. UB-311 is an anti–amyloid-β active immunotherapeutic vaccine shown to be well-tolerated and to have a ...
Hui Jing Yu, Samuel P. Dickson, Pei-Ning Wang, Ming-Jang Chiu, Chin-Chang Huang, Chiung-Chih Chang, Hope Liu, Suzanne B. Hendrix, Jean-Cosme Dodart, Ajay Verma, Chang Yi Wang, Jeffrey Cummings   +11 more
doaj   +1 more source

Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study [PDF]

, 2021
To investigate the natural history and outcomes following treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like in cerebral amyloid angiopathy-related inflammation (CAA-ri)
Pascarella, Rosario, Masafumi Ihara, Perini, Giulia, Shima, Atsushi, Ricardo Nitrini, Roberto Marconi, Maria Sessa, Laura Antolini, Domenico Inzitari, Rosario Pascarella, Valenti, Raffaella, Gianpaolo Basso, Di Lazzaro, Vincenzo, Alessia Giossi, Charidimou, Andreas, Andreas Charidimou, Marcon, Michela, Roxana O. Carare, Andrea Arighi, Carare, Roxana, Tagliavini, Fabrizio, Elio Scarpini, and Fabrizio Piazza, Jacopo C. DiFrancesco, Mario Cirillo, Hagiwara, Yuta, Zedde, Marialuisa, Raffaella Valenti, Fabrizio Tagliavini, Berardino Orlandi, Villarejo-Galende, Alberto, Carare, Roxana O, Carlo Ferrarese, Vincenzo Di Lazzaro, Marialuisa Zedde, Sessa, Maria, Inzitari, Domenico, Arighi, Andrea, Basso, Gianpaolo, Marconi, Roberto, Nitrini, Ricardo, Cirillo, Mario, Michela Marcon, Ziliotto, Nicole, Alessandro Padovani, Alberto Villarejo-Galende, Yuta Hagiwara, Scarpini, Elio, Massimo Caulo, Francesco Perini, Piazza, Fabrizio, Cagnin, Annachiara, Caulo, Massimo, Juan Francisco Vazquez-Costa, Nicole Ziliotto, Antolini, Laura, Vázquez-Costa, Juan Francisco, Ferrarese, Carlo, Padovani, Alessandro, Ihara, Masafumi, Perini, Francesco, Atsushi Shima, DiFrancesco, Jacopo C, Annachiara Cagnin, Giossi, Alessia, Giulia Perini, Orlandi, Berardino, Ziliotto N., Caulo M., Scarpini E., Charidimou A., Marcon M., Marconi R., Carare R. O., Piazza F., Padovani A., Sessa M., Tagliavini F., Orlandi B., Arighi A., Perini F., Basso G., Giossi A., Cirillo M., Villarejo-Galende A., Cagnin A., Di Lazzaro V., Valenti R., Antolini L., Ferrarese C., Pascarella R., Nitrini R., DiFrancesco J. C., Shima A., Ihara M., Hagiwara Y., Perini G., Zedde M., Vazquez-Costa J. F., Inzitari D., Fabrizio Piazza   +100 more
core   +1 more source

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice [PDF]

, 2022
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities.
Ramanan, VK, Cogswell, PM, Benzinger, TS, Jack, CR, Whitlow, CT, Barkhof, F, Raji, CA, Poussaint, TY, Barakos, JA   +8 more
core   +1 more source

Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report

Radiology Case Reports, 2023
Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging
Houman Sotoudeh, MD, Mohammadreza Alizadeh, MD, Ramin Shahidi, MD, Parnian Shobeiri, MD, MPH, Natelson love, MD, Aparna Singhal, MD   +5 more
doaj   +1 more source

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics [PDF]

, 2023
Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target ...
Elhage, Aya, Hampel, Harald, Cho, Min, Aya Elhage, Liana G Apostolova, James A R Nicoll, Apostolova, Liana G., Harald Hampel, Alireza Atri, Min Cho, Atri, Alireza, Nicoll, James A. R., Nicoll, James A.R.   +12 more
core   +1 more source